To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease (World Pharma News)
Diabetes News Service
To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease (World Pharma News)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales